Advertisement
Advertisement
U.S. Markets open in 1 hr 47 mins
Advertisement
Advertisement
Advertisement
Advertisement

PharmaCyte Biotech, Inc. (PMCB)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.0400+0.0100 (+0.33%)
At close: 03:59PM EST
2.7600 -0.28 (-9.21%)
After hours: 06:15PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.0300
Open3.0300
Bid0.0000 x 1100
Ask3.0900 x 900
Day's Range2.9588 - 3.1000
52 Week Range1.7900 - 3.1000
Volume26,901
Avg. Volume93,753
Market Cap62.976M
Beta (5Y Monthly)0.01
PE Ratio (TTM)N/A
EPS (TTM)-0.0020
Earnings DateDec 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

    Topics to Include Continued Analysis of FDA’s Clinical Hold on IND for Cell-in-a-Box®LAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box for potential development of cellular therapies for cancer, diabetes and malignant ascites, announces today that its Board of Directors has empowered its Business Review Committee to evalu

  • Business Wire

    PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

    LAS VEGAS, August 15, 2022--PharmaCyte and Iroquois have reached a settlement which includes appointing five new independent directors to PharmaCyte's reconstituted Board.

  • Business Wire

    PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation

    LAS VEGAS, July 28, 2022--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the following statement in response to Iroquois Capital’s filing of a preliminary consent statement to commence a consent solicitation in lieu of a stockholder meeting. Iroquois Capital is seeking the consent of the Company’s shareholders

Advertisement
Advertisement